Physiologically based pharmacokinetic modeling of cyclotrimethylenetrinitramine in male rats

Journal of Applied Toxicology

Volumn 29, Issue 7, 2009, Pages 629-637

  Krishnan, Kannan ^a   Crouse, Lee C B ^b   Bazar, Matthew A ^b   Major, Michael A ^b   Reddy, Gunda ^b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b U S ARMY CENTER FOR HEALTH PROMOTION AND PREVENTIVE MEDICINE   (United States)

Author keywords

PBPK model; Pharmacokinetics; RDX

Indexed keywords

CYCLONITE;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ARTICLE; BRAIN TISSUE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; GASTROINTESTINAL ABSORPTION; LIPOPHILICITY; LIVER; LIVER CLEARANCE; MALE; MUSCLE TISSUE; NONHUMAN; PRIORITY JOURNAL; RAT; SYSTEMIC CIRCULATION;

ADMINISTRATION, ORAL; ALGORITHMS; ANIMALS; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; EXPLOSIVE AGENTS; INJECTIONS, INTRAVENOUS; KINETICS; MALE; MODELS, BIOLOGICAL; RATS; RATS, INBRED F344; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY; TISSUE DISTRIBUTION; TRIAZINES;

RATTUS;

EID: 70350238651     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.1455     Document Type: Article

References (25)

1. ATSDR. 1995. Toxicological Profile for RDX. US Department of Health and Human Services, Public Health Service, Agency for Toxic Substances and Disease Registry: Atlanta, GA.
2. Bhushan B, Trott S, Spain JC, Halasz A, Paquet L,Hawari J. 2003. Biotransformation of hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) by a rabbit liver cytochrome P450: insight into the mechanism of RDX biodegradation by Rhodococcus sp. strain DN22. Appl. Environ. Microbiol. 69: 1347-1351.
3. Bishop RW, Hable MA, OliverCG, Valis RJ. 2003. The USACHPPM gas chromatographic procedure for the analysis of waters and soils for energetic and related compounds. J. Chromatogr. Sci. 41: 73-79.
4. Clewell HJ III, Andersen ME. 1985. Risk assessment extrapolations and physiological modeling. Toxicol. Ind. Health 1: 111-131.
5. Clewell HJ III, Andersen ME, Barton HA. 2002. A consistent approach for the application of pharmacokinetic modeling in cancer and noncancer risk assessment. Environ. Health Perspect. 110: 85-93.
6. Crouse LCB, Michie MW, Major MA, Leach GJ, Reddy G. 2008. Oral bioavailability of cyclotrimethylenetrinitramine (RDX) from contaminated site soils in rats. Int. J. Toxicol. 27: 317-322.
7. Hart ER 1976. Two Year Feeding Study in Rats. Litton Bionetics Inc.: Kensington, MD. Office of Navel Research Contract number N00014-73-C-0162. ADA 040161.
8. Krishnan K, Andersen ME 2001. Physiologically based pharmacokinetic modeling in toxicology. In Principles and Methods of Toxicology, Hayes AW (ed.). Taylor & Francis: Philadelphia, PA; 193-241.
9. Levine BS, Furedi-Machacek EM, Rac VS, Gordon DE, Lish PM. 1983. Determination of the Chronic Mammalian Toxicological Effects of RDX: Twenty-four Month Chronic Toxicity/carcinogenicity Study of Hexahydro- 1,3,5-trinitro-1,3, 5-triazine (RDX) in Fisher 344 Rat. Phase V, Vol.1. Contract no. DAMD 17-79-C-9161. IIT Research Institute: Chicago, Illinois. ADA 160774. US Army Medical Research and Development Command: Fort Detrick, MD.
10. Lipscomb JC, Ohanian EV. 2007. Toxicokinetics and Risk Assessment. Informa Healthcare: New York.
11. Lish PM, Levine BS, Furedi-Machacek EM, Sagartz EM, Rac VS. 1984. Determination of the Chronic Mammalian Toxicological Effects of RDX: Twenty-four Month Chronic Toxicity/carcinogenicity Study of Hexahydro- 1,3,5-trinitro-1,3, 5-triazine (RDX) in B6C3F1 Hybrid Mouse. Phase VI, Vol 1. Contract no. DAMD 1-79-C-9161. IIT Reserach Institute: Chicago, Illinois. ADA160774. U.S. ArmyMedical research and development Command: Fort Detrick, MD.
12. Major MA,Reddy G, Berge MA, Patzer SS, Li AC, Gohdes M. 2007. Metabolite profiling of [14C]hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) in Yucatan miniature pigs. J. Toxicol. Environ. Health A 70: 1191-1202
13. McLellan WL, Hartley WR, Brower ME. 1992. Hexahydro-1,3,5-trinitro- 1,3,5-triazine (RDX). In Drinking Water Health Advisory: Munitions, Roberts WC, Hartley WR (eds). Lewis:, Boca Raton, FL; 133-180.
14. NRC. 1996. Guide for the Care and Use of Laboratory Animals. Institute of Laboratory Animal: Resources commission on Life sciences, National Research Council. National Academy Press: Washington DC.
15. Parker GA, Reddy G, Major MA. 2006. Reevaluation of a twenty-four-month chronic toxicity/carcinogenicity study of hexahydro-1,3,5-trinitro-1,3,5- triazine (RDX) in the B6C3F1 hybrid mouse. Int. J. Toxicol. 25: 373-378.
16. Poulin P, Krishnan K. 1995. An algorithm for predicting tissue: blood partition coefficients of organic chemicals from n-octanol: water partition coefficient data. J. Toxicol. Environ. Health. 46: 117-129.
17. Poulin P, Krishnan K. 1996. Molecular structure-based prediction of the partition coefficients of organic chemicals for physiological pharmacokinetic models. Toxicol. Meth. 6: 117-137.
18. Poulin P, Theil FP. 2000. A priori prediction of tissue : plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. J. Pharm. Sci. 89: 16-35.
19. Ramsey JC, Andersen ME. 1984. A physiologically based description of the inhalation pharmacokinetics of styrene in rats and humans. Toxicol. Appl. Pharmacol. 73: 159-175.
20. Reddy G, Erexson GL, Cifone MA, Major MA, Leach GJ. 2005. Genotoxicity assessment of hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX). Int. J. Toxicol. 24: 427-438.
21. Schneider NR, Bradley SL, Andersen M E. 1977. Toxicology of cyclotrimethylenetrinitramine: distribution and metabolism in the rat and the miniature swine. Toxicol. Appl. Pharmacol. 39: 531-541.
22. Thompson CM, Sonawane B, Barton HA, DeWoskin RS, Lipscomb JC, Schlosser P, Chiu WA, Krishnan K. 2008. Approaches for applications of physiologically based pharmacokinetic models in risk assessment. J. Toxicol. Environ. Health B Crit. Rev. 11: 519-547.
23. Timchalk C, Nolan RJ, Mendrala AL, Dittenber DA, Brzak KA, Mattsson JL. 2002. A physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model for the organophosphate insecticide chlorpyrifos in rats and humans. Toxicol. Sci. 66: 34-53.
24. Trudnowski RJ, Rico RC. 1974. Specific gravity of blood and plasma at 4 and 37°C. Clin. Chem. 20: 615-616.
25. US EPA. 2006. Approaches for the application of physiologically based pharmacokinetic (PBPK) models and supporting data in risk assessment. EPA/600/R-05/043F. 2006. National Center for Environmental Assessment, Office of Research and Development, US Environmental Protection Agency: Washington, DC.